Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined oncology professionals around the world for the 2020 ASCO Virtual Scientific Program, held online for the first time, from May 29 through May 31, 2020. The virtual meeting delivered the latest cancer science in a diverse program, and featured over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and specialty tracks.
From early phase clinical trials to health services research studies, rare malignancies to prevalent cancers, and prevention to survivorship, the more than 20 abstracts reflected our breadth of investigation to advance cancer science and medicine. Highlights included oral presentations and discussion at sessions for Developmental Therapeutics, Head and Neck Cancer, Symptoms and Survivorship, and a clinical science symposium on Drug Development for Rare Mutations.
Of note, Rachel E. Sanborn, M.D., associate member and co-director of the Providence Thoracic Oncology Program, was an invited discussant for the oral abstract session on Lung Cancer - Non-Small Cancer Metastatic where she gave her presentation “Maximizing the Benefits of (EGFR) Targeted Therapies.” Additionally, Dr. Sanborn was invited by Springer Healthcare, an ASCO20 partner, to provide her expert opinion on the top two most impactful lung cancer abstracts from this year’s meeting, Abstract #LBA5 “Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA” and Abstract #9501 “Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non-small cell lung cancer: CheckMate 9LA.”
View all our abstracts and links to further reading below:
Clinical Science Symposium
Drug Development for Rare Mutations: The Opportunity to Unite and Conquer!
Abstract 109: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. V Subbiah…M Taylor et al.
Oral Abstract Session
Developmental Therapeutics – Immunotherapy
Abstract 3003: Safety and Tolerability of MEDI0562 in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors. JW Goldman…BD Curti et al.
Abstract 3005: PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. F Thistlethwaite…RE Sanborn et al.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract 3502 - CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. ML Johnson…RE Sanborn et al.
Head and Neck Cancer
Abstract 6500 - Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). RL Ferris…RB Bell et al.
Symptoms and Survivorship
Abstract 12005: Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia: A URCC NCORP Research Base Phase III RCT in 740 cancer survivors. KM Mustain…AK Conlin et al.
Poster Discussion Session
Developmental Therapeutics – Immunotherapy
Abstract 3011: Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. M Shafique…RE Sanborn et al.
Poster Session
Breast Cancer – Local/Regional/Adjuvant
Abstract 526: CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). V Boni…RE Sanborn et al.
Breast Cancer – Metastatic
Abstract 1043: Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). AFC Okines…AK Conlin et al.
Developmental Therapeutics – Immunotherapy
Abstract 3112: A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment. AB El-Khoueiry…RE Sanborn et al.
Abstract TPS3171 - A phase I/II study of HB-201, an arenavirus-based cancer immunotherapy, alone, or in combination with anti-PD-1 in patients with HPV16+ cancers. B Burman…RS Leidner et al.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract 3552: A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors. AS Mansfield…M Taylor et al.
Gastrointestinal Cancer—Colorectal and Anal
Abstract 4105 - Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients. J Galon…CB Bifulco...BA Fox et al.
Gynecologic Cancer
Abstract 6083: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC). V Makker…M Taylor et al.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract 8037 - Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). CR Bachier…JE Godwin et al.
Abstract 8040 - Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study. A Sehgal…JE Godwin et al.
Lung Cancer – Non-Small Cell Metastatic
Abstract 9546 - Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. D. Morgensztern…B Piening et al.
Symptoms and Survivorship
Abstract 12099: Inflammatory and clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN): A nationwide longitudinal study in 143 cancer patients during chemotherapy. I Kleckner…AK Conlin et al.
Publication
Breast Cancer - Local/Regional/Adjuvant
Abstract 12589: Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast. K Sanchez…WL Redmond, B Bernard, WJ Urba, DB Page et al.
Health Services Research and Quality Improvement
Abstract 19300 - Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): Retrospective, longitudinal data analysis. RS Epstein…RE Sanborn et al.
Melanoma/Skin Cancer
Abstract e22050 - An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts. MR Middleton…BD Curti et al.
All abstracts from ASCO20 Virtual: Scientific Program are available online. You can also view the Digital Program and explore the Virtual Exhibits.
